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INTRODUCTION 
Little is known on the biochemical reactions that are the basis for the mode of 
action of anticonvulsants in man. For sodium valproate, the increase in the concentra- 
tion of y-amino-butyric acid could be the mode of action.' In contrast to sodium 
valproate, all clinically used anticonvulsants contain a carbamide group, which in most 
cases is cyclic (FIG. 1). A possible common biochemical mechanism of action of these 
anticonvulsants could be the reduction of circulating folate, which also has a cyclic 
carbamide group, observed under anticonvulsant treatment.* Biotin too has a cyclic 
carbamide group and has not been investigated in epileptics until now. This vitamin 
seems of interest for various reasons: it serves as the prosthetic group of pyruvate, 
propionyl-CoA, 3-methylcrotonyl-CoA and acetyl-CoA carboxylases and has a central 
function in the metabolism of carbon dioxide. Carbon dioxide is known to have an 
important influence on the seizure thre~hold .~  The biotin-dependent carboxylases are 
involved in the metabolism of some neurotransmitters. Our first results indicated a 
marked reduction of biotin in the plasma of epileptics under long-term therapy with 
anticonv~lsants.~.~ Starting from this observation the following questions were investi- 
gated: 
(1) Can the tendency of a reduced plasma biotin concentration be confirmed in a 
larger'collective of epileptics? Are there connections between the amount, type, and 
serum level of the anticonvulsants used or between the type of epilepsy or seizure and 
the observed levels of biotin in plasma? 
(2) Are there signs of a biochemical effect of the reduced biotin levels when 
concentrations of organic acids in urine and plasma are determined? 
BIOTIN LEVEIS IN PLASMA UNDER LONG-TERM THERAPY WITH 
ANTICONVULSANTS 
Patients and Methods 
Biotin plasma concentrations were determined by a microbiological assay?' using 
Lactobacillus plantarum as a test organism in 404 patients (235 men, 169 women) 
'Dedicated to Professor H. Ganshirt, Director of the Neurological Clinic, University of 
Heidelberg on the occasion of his 65th birthday. This work was supported in part by Grant Kr 
659/1 from the Deutsche Forschungsgemeinschaft. 
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FIGURE 1. Chemical structure of commonly used anticonvulsants and of biotin (carbamid 
groups are marked by thick lines). 
attending the Heidelberg out-patient clinic for epileptics. The patients were between 
20 and 40 years old. One-hundred and ninety-four patients had a partial and 210 a 
generalized epilepsy. Fifty-six patients showed partial seizures with elementary 
symptomatology, which were combined in part with tonic clonic seizures and/or 
partial seizures with complex symptomatology, 68 showed absences without known 
organic etiology and/or impulsive-petit-ma1 epilepsy, which mostly were combined 
with tonic-clonic seizures. At the time of examination 62 patients were treated in 
monotherapy with primidone (PRM), 40 with carbamazepine (CBZ), 39 with 
phenytoin (PHT), 21 with sodiunl valproate (VPA), and 14 with phenobarbital (PB). 
The other epileptics received a combined therapy with these or other anticonvulsants. 
Using equivalent units we calculated the average daily dose of anticonvulsants for each 
of these patients (1 equivalent unit = 50 mg phenytoin, 30 mg phenobarbital, 125 mg 
primidone, 200 mg carbamazepine, 250 mg ethosuximide, 300 mg sodium valproate, 
50 mg mesantoin, 2 mg clonazepam, 300 mg mesuximide, 100 mg sulthiame, or 250 
mg oxazolidine). The plasma levels of phenytoin, phenobarbital, primidone, carbama- 
zepine, and sodium valproate were determined by gas chromatography or by 
enzymatic immunoassay. The patients were clinically tested especially in view of 
possible cerebellar dysfunctions or dermatological disturbances. One-hundred and 
twelve persons were used as controls (24 volunteers of the clinic staff, 40 blood donors 
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and 48 patients with dermatological diseases, who had shown no differences in biotin 
levels compared with a normal population'); the mean age of the controls was 42.3 2 
14.5 years, 67 were male and 45 female. Student's t-test was used for the comparison of 
biotin concentrations between patients with generalized and partial epilepsy and 
between patients with absences and partial seizures with elementary symptomatology, 
for the comparison of biotin values of patients with low or high average daily 
anticonvulsant doses, and for the comparison of biotin levels of epileptics with or 
without cerebellar signs. Connections between biotin concentrations in plasma and 
average daily dose or serum concentrations of anticonvulsants in patients under 
monotherapy were evaluated by linear regression analysis. The patients on monother- 
apy with phenytoin, carbamazepine, primidone, phenobarbital, or sodium valproate as 
well as patients with or without dermatological disturbances were compared using 
variance analysis. 
Results 
The mean biotin plasma concentration of the 404 long term-treated epileptics was 
0.90 0.29 nmol/l. This value is significantly (p < 0.0005) lower than the 1.63 2 0.49 
nmol/l found in the control group (FIG. 2). The 210 patients with generalized epilepsy 
showed higher biotin values (0.94 2 0.27 nmol/l) than the 194 patients with partial 
epilepsy (0.86 2 0.30 nmol/l; p < 0.005) (FIG. 3). The latter had a higher average 
daily intake of anticonvulsants (7.54 2 3.25 equivalent units/d) than the former 
(6.92 2 3.07 equivalent units/d) (p < 0.05) (FIG. 4). Plasma biotin concentrations of 
patients with partial seizures with elementary symptomatology were lower than, but 
35 106-U5 12€-1(5 la-165 166-185 165-205 >205 biotin mblasrna 
l;rnol/l) 
FIGURE 2. Distribution of plasma biotin concentrations in epileptics and controls. 
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did not differ significantly from, those of epileptics with absences without known 
etiology or with impulsive-petit-ma1 epilepsy (0.90 f 0.28 nmol/l compared with 0.98 
2 0.30 nmol/l). 
The biotin concentrations of patients on monotherapy are summarized in FIGURE 5. 
Whereas no significant differences were found between the values of patients treated 
with primidone, carbamazepine, phenytoin, or phenobarbital, the levels in epileptics 
treated with sodium valproate alone were significantly higher. A probable negative 
correlation between plasma biotin levels and serum concentrations of anticonvulsants 
in patients under monotherapy resulted only for the phenytoin group (correlation 
coefficient r = -0.295, 0.1 > p > 0.05). The 6 patients with the highest phenytoin 
serum levels ( I  5.0-22.8 pg/l) had very low biotin concentrations of less than 0.82 
nmol/l. 
Evaluation of the relationship between average daily dose of anticonvulsants in 
equivalent units per day and biotin plasma concentrations in all 404 epileptics resulted 
in a weak negative correlation (r = -0.0754,O.l > p > 0.05). The group of epileptics 
with a high average daily dose of anticonvulsants ( > l o  equivalent units per day; n = 
84) showed significantly (p < 0.0025) lower plasma biotin concentrations (0.88 0.25 
nmol/l) than the group with a low dose ( < 5  equivalent units per day; n = 71, 0.97 * 
0.28 nmol/l) (FIG. 6). 
The plasma biotin concentration in 80 epileptics with at  least one symptom of 
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FIGURE 4. Average daily intake of anticonvulsants in patients with generalized and partial 
epilepsies (- = mean value; ----- = standard deviation). 
cerebellar dysfunction (nystagmus, ataxia, cerebellar dysarthria) was 0.83 2 0.23 
nmol/l and differed significantly from that of the other epileptics (0.92 * 0.29 nmol/l) 
(p < 0.01). Eighty-five percent of the epileptics with cerebellar dysfunction had 
plasma biotin concentrations <1.02 nmol/l compared with 73.8 percent of the others 
(FIG. 7). Dermatological disturbances like exfoliative dermatitis were not seen in our 
patients. Sixty-three epileptics suffered from acne, 26 from milder forms of eczema- 
tous dermatitis. The average biotin concentrations of these patients and the other 
epileptics are given in TABLE 1; the values did not differ significantly. 
BIOTIN PLASMA CONCENTRATIONS BEFORE AND AFl’ER STARTING 
ANTICONVULSANT THERAPY 
To evaluate the effect of an anticonvulsant medication on biotin levels, plasma 
concentrations have to be measured in patients with newly recognized epilepsy before 
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FIGURE 7. Plasma biotin concentration in epileptics with (group 1)  and without (group 2) signs 
of cerebellar dysfunction (- = mean value; ----- = standard deviation). 
the start of anticonvulsant therapy and thereafter. Up to now we have had the 
opportunity to follow 3 patients in this way. 
Patients and Methods 
Patient 1 was a 61-year-old man with an ischemic infarction of the left posterior 
lobe, verified by cerebral computertomography, and which was caused by angiographi- 
TABLE I .  Concentrations of Biotin (% k s.d.) in Plasma of Epileptics with Acne or 
Eczematous Dermatitis and in Patients without Dermatological Signs 
Biotin in Plasma 
n (nmol/ 1 ) 
Acne 63 
Eczematous dermatitis 26 
Other epileptics 315 
0.87 t 0.38 
0.91 r 0.25 
0.91 t 0.27 
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cally evaluated marked stenosis of the left posterior cerebral artery. There was a 
diabetes mellitus as additional risk factor. One year after the cerebral insult a 
generalized tonic clonic seizure with a right focal beginning occurred; as no unexpected 
changes in computertomography were seen, this seizure was classified as the first sign 
of a vascular epilepsy. The patient was given 3 x 100 mg phenytoin per day. 
Patient 2 was a 42-year-old woman, who had two generalized tonic clonic seizures, 
beginning with left-sided partial seizures of elementary symptomatology 5 years after 
ablatio mammae because of carcinoma solidum simplex. Computer tomography 
showed a cerebral metastasis localized in the right precentral region. Treatment with 
3 x 100 mg phenytoin per day was initiated. 
Patient 3 had two generalized tonic clonic seizures after lack of sleep at  the age of 
25. The electroencephalogramm showed bilateral synchronous spike waves under 
hyperventilation; the cranial computertomography was normal. A genuine epilepsy 
was diagnosed. Anticonvulsant therapy with 3 x 250 mg primidone per day was 
started. Plasma biotin concentrations were determined in samples taken before and up 
to 6 months after the start of therapy. 
Results 
Plasma biotin concentrations of the three patients are shown in FIGURE 8. Before 
starting anticonvulsant medication no patient had a low biotin level. In all patients the 
biotin in plasma (nmol/I 
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FIGURE 8. Plasma biotin concentrations of 3 epileptics before (t,) and after (tZ - 1 week, t, - 8 
weeks, t, = 16 weeks, t, = 26 weeks) start of anticonvulsant therapy. 
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biotin concentration increased during the first week of therapy, and fell below the 
starting level in the following weeks. In patient 3, after half a year on antiepileptic 
treatment, a subnormal biotin concentration of less than 0.92 nmol/l was determined. 
BIOTIN-DEPENDENT ORGANIC ACIDS IN THE URINE OF EPILEPTICS 
UNDERGOING LONG-TERM TREATMENT 
One of the most important criteria for the diagnosis of an inborn error of 
biotin-dependent carboxylases9 or dietary deficiency of biotin"." is the detection of 
defined organic acids in urine, known to be elevated in biotin deficiency. Typically, a 
reduced activity of 3-methyl-crcitonyl-CoA carboxylase leads to an elevated excretion 
of 3-methylcrotonic acid, of its product of hydration (3-hydroxyisovaleric acid), and of 
3-methylcrotonylglycine formed by conjugation with glycine (see FIG. 9). An increased 
excretion of 3-hydroxypropionic acid, propionylglycine and methylcitric acid is caused 
by a reduced activity of propionyl-CoA carboxylase; further metabolites, which may be 
elevated when the activity of this carboxylase is deficient, are tiglic acid, tiglylglycine 
and 2-methyl-3-hydroxybutyric acid, derived from the catabolism of isoleucine (see 
FIG. 10). Elevation of lactic acid, which is in balance with pyruvic acid, has been 
described as a typical pattern in a deficiency of pyruvate carboxylase activity. If the 
reduced levels of biotin found in epileptics cause a decrease in the activity of 
biotin-dependent carboxylases, then abnormal organic acids should be detected in the 
urine of patients on chronic anticonvulsant therapy. 
Patients and Methods 
Twenty-four hour urine samples were collected from 6 male epileptics, aged 22 to 
37 years, who had been under anticonvulsant treatment for a t  least one year. Organic 
acids were determined as trimethylsilyl derivatives by combined gas-chromatography 
and mass spectroscopy.'* Type of seizures and serum levels of anticonvulsants given at  
the time of examination are compiled in TABLE 2. Blood was taken for microbiological 
determination of biotin in plasma on the morning after collection of 24-h urine. Three 
healthy persons (2 men, 30 and 34 years old, 1 woman, 27 years old) served as 
controls. 
Results 
In the four epileptics treated with phenytoin, primidone, carbamazepine or 
phenobarbital elevated concentrations of a t  least two of the three metabolites were 
found (FIG. 9), which are known to occur due to a deficiency of 3-methylcrotonyl-CoA 
carboxylase. The concentrations of the two acids, which appear after the carboxylation 
step in the catabolism of leucine, were lower in the urines of these four epileptics 
compared with the concentrations in the other urines. Furthermore, the plasma biotin 
concentrations were markedly lower in the four epileptics treated with phenytoin, 
primidone, carbamazepine or phenobarbital than in the two patients treated with 
sodium valproate, or in the three controls. At least three of the metabolites, which can 
be increased in a deficiency of propionyl-CoA carboxylase activity, were elevated in 
the urines of three of the four epileptics treated with other anticonvulsants than sodium 
valproate (FIG. lo), whereas the levels of these compounds were normal in the 
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epileptics under sodium valproate and in controls. Lactate concentrations in the urines 
of the four epileptics not treated with sodium valproate were markedly higher than in 
the other subjects (FIG. 11). 
LACTATE IN PLASMA OF EPILEPTICS UNDERGOING 
LONG-TERM TREATMENT 
Deficiency of pyruvate carboxylase activity can also lead to an elevation of plasma 
lactate levels. Therefore, the plasma lactate concentrations were determined in some 
long-term treated epileptics and compared with those of a control group. 
Patients and Methods 
Thirty-seven epileptics (24 men, 13 women) of the Heidelberg outpatient clinic for 
epileptics, aged 20 to 42 years, were investigated. The patients were treated for a t  least 
one year with anticonvulsants, mostly in combination therapy. The controls were 16 
healthy persons (9 men, 7 women) aged 20 to 46 years, who took no medication. After 
short compression for 30 seconds, 2 ml venous blood was taken from the fasting 
subjects. The blood was mixed immediately with 2 drops fluoride/EDTA. Lactate was 
determined using an enzymatic test in modification of the method described by N ~ l l . ' ~  
The lactate concentrations of the two groups were compared using Student's t-test. 
Results 
The epileptics undergoing long-term treatment had a mean plasma lactate 
concentration of 1.32 f 0.44 mmol/l, which was higher than that found in controls 
(1.05 t 0.32 mmol/l; p < 0.05). The individual levels are given in FIGURE 12. 
lactic acid in urine (umol/mg creatinine) 
09 
0 4  
03 
02 
01 ll 2 3  FIGURE 11. Lactic acid concentration in --- 
epileptics treated with Controls 
PHT, PRM,CBZ,or PB 
( I - & )  Or VPA15,61 
KRAUSE ef al.: BIOTIN STATUS OF EPILEPTICS 309 
lactic ac 
2 .S 
2 .o 
1.5 
1.0 
0 5  
1 in plasma lmmo I /I) 
0 
0 
epileptics controls 
FIGURE 12. Concentration of lactic acid in plasma of 37 long-term treated epileptics and 16 
controls (- = mean value; ----- - standard deviation). 
DISCUSSION 
The presented results illuminate some interesting aspects of the relationship 
between biotin status and anticonvulsant therapy in epileptics. The plasma biotin 
concentrations of epileptics under long-term treatment with anticonvulsants are 
markedly reduced. The degree of biotin reduction clearly exceeds that of other vitamin 
deficiencies seen in chronic anticonvulsant therapy e.g. of folate or 25-hydroxychole- 
~alciferol . '~  The plasma biotin concentrations of patients under monotherapy with 
sodium valproate are higher than those of epileptics treated with other anticonvulsants. 
This finding seems to be of interest since valproate differs chemically from the other 
anticonvulsants and from biotin. 
It seems that the observed reduction of biotin levels is caused by the intake of 
anticonvulsant and is not a sign of lthe underlying disease itself. The biotin concentra- 
tion of some untreated epileptics was normal and epileptics suffering from generalized 
epilepsies, who should apriori have a higher genetic disposition than those with partial 
epilepsies, showed a higher mean biotin concentration than the latter. 
310 ANNALS NEW YORK ACADEMY OF SCIENCES 
The fact that there was a higher mean intake of anticonvulsants in partial epilepsy, 
confirms the assumption that the reduction of biotin levels is a drug effect. The 
negative correlation approaching significance between the average daily intake of 
anticonvulsants and the plasma biotin concentrations and the significantly higher 
biotin concentrations found in epileptics with a low average daily intake of anticonvul- 
sants further confirm the effect of anticonvulsants on biotin status. 
At this time only speculations on the mechanism for the reduction of biotin levels in 
epileptics are possible. The initial increase in plasma biotin concentration, observed in 
patients after starting anticonvulsant therapy, could be due to a blockage in the uptake 
of biotin into human tissues or due to a release of biotin from stores by anticonvulsants. 
Further investigations will show whether competitive interactions, disturbances in 
absorption, hepatic induction of enzymes catabolizing or consuming biotin, or 
influences on the enteral biotin synthesis play a role in the reduction of biotin levels by 
anticonvulsants. 
The reduced biotin status seen in epileptics has a biochemical effect in elevating the 
concentration of certain organic acids in blood and urine. Previously, such an increase 
was only known to occur in children with an inborn error of biotin-dependent enzymes 
and in children with a dietary biotin deficiency.’’ 
The reduction of biotin levels could be a factor in the mode of action of 
anticonvulsants: a reduced activity of biotin-dependent carboxylases could result in a 
higher cerebral concentration of free carbon dioxide, a mechanism, which would 
elevate the seizure threshold. Especially pyruvate carboxylase is known to be the 
essential enzyme for fixing carbon dioxide in the brain.I5 If the concentration of carbon 
dioxide is too elevated, the seizure threshold will finally fall under the starting  level.'"^'' 
This mechanism could explain the seizures seen in phenytoin i n t o x i ~ a t i o n ’ ~ * ~ ~  and in 
inborn errors of biotin-dependent enzymes. Accordingly no beneficial effects with the 
exception of sodium valproate” have been described when affected children were given 
a n t i c o n ~ u l s a n t s . ” ~ ~ ~  Only in one patient with a non-biotin-dependent isolated defi- 
ciency of pyruvate carboxylase activity were phenobarbital, phenytoin and diazepam, 
found to have some benefit.’5 A reduced pyruvate carboxylase activity can lead to a 
decrease of oxalacetate, which is essential for the de now synthesis of aspartate.26 
Aspartate is known to be an excitatory neurotransmitter, and decreased concentrations 
have been found in some areas of the brain of animals when given phenytoin.” This 
could be a further biotin-dependent mechanism in the mode of action of anticonvul- 
sants. Furthermore, oxalacetate is a key intermediate in the tricarboxylic acid cycleZ8 
and is assumed to play a very important role in the anaplerotic metabolism of the 
brain.29 It seems therefore possible, that a deficiency of pyruvate carboxylase activity 
could additionally lower the seizure threshold via blocking the energy production in the 
citrate cycle. Furthermore, an elevation of the inhibitory neurotransmitter glycine can 
be postulated as possible consequence of reduced biotin levels: as a decreased activity 
of pyruvate carboxylase, which is essential for the catabolism of serin and consequently 
of glycine, or of propionyl-CoA carboxylase, via the metabolism of methionine and 
threonine, could elevate glycine levels.’ 
The reduced biotin levels could play a role in some well-known side effects of 
anticonvulsants, such as the cerebellar disturbances often described as a symptom in 
nutritional biotin deficiency or in patients with a deficient activity of biotin-dependent 
carboxyla~es.~ In our sample lower mean biotin concentrations were found in patients 
with cerebellar signs than in the other epileptics, and this may be seen as an indication 
of a possible causal relationship. For the same reason other authors postulated a 
connection between the reduced levels of folate and the ataxia caused by anticonvul- 
sants.” The serum phenytoin concentrations are known to correlate strongly with the 
appearance and the degree of cerebellar symptoms;”*32 and only the serum levels of this 
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anticonvulsant showed a negative correlation with the plasma biotin concentrations 
which almost reached significance. Whereas cerebellar symptoms as sign of an 
overdose of phenytoin, carbamazepine, and not so often of primidone or phenobarbi- 
ta1,33 can occur a t  any time of a long-term anticonvulsant treatment and may also 
persist in some an exfoliative dermatitis is described as a severe allergic 
reaction only during the first weeks of anticonvulsant medication with the consequence 
of discontinuing the drug.” Therefore, it is not surprising that in our group of 
long-term treated epileptics no patients with exfoliative dermatitis were detected. As in 
nonepileptic subjects,* no difference in mean biotin levels was noted in epileptics with 
and without other dermatologic manifestations (acne or eczematous dermatitis). 
Further research is needed to verify possible correlations between biotin status and 
findings in treated epileptics such as elevated cholesterol levels’* also reported in cases 
of pyruvate carboxylase deficiency*’ as well as in nutritional biotin defi~iency,’’,~ or 
disturbances of the immunoregulatory system, noted in inborn errors of metabolism of 
biotin-dependent carbo~ylases!’~’ Furthermore, the teratogenic effect of biotin 
deficiency in animals” might be connected to the teratogenicity of anticonvulsants and 
deserves further attention. 
SUMMARY 
Microbiologically determined plasma biotin levels in 404 epileptics under long- 
term treatment with anticonvulsants were markedly lower than in 112 controls (p < 
0.0005). Patients with partial epilepsy had lower biotin levels and higher average daily 
intake of AC than those with generalized epilepsy. Epileptics treated with valproate 
sodium in monotherapy showed considerably higher biotin levels than epileptics with 
monotherapy of primidone (PRM), carbamazepine (CBZ), phenytoin (PHT) or 
phenobarbital (PB). The group of epileptics with high average daily dose of anticonvul- 
sants had lower biotin levels than the group with low dose. In three patients with newly 
recognized epilepsy biotin levels were normal before starting anticonvulsant medica- 
tion, increased during the first week and fell under the starting level in the following 
weeks. Four epileptics treated with PHT, PB, PRM or CBZ had an increased urinary 
excretion of organic acids, as found in patients with a deficiency of biotin-dependent 
carboxylases. In 37 epileptics undergoing long-term treatment plasma lactate concen- 
trations were determined; they had a higher mean concentration than that found in 
controls. Our results suggest, that the lowering of biotin in epileptics (1) is caused by 
intake of anticonvulsants and (2) has a biochemical effect in these patients. It is 
discussed, whether this could be a factor in the mode of action of anticonvulsants. 
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DISCUSSION OF THE PAPER 
H. N. BHAGAVAN (Hoffmann-La Roche, Inc., Nutley. NJ): Did you see any 
K.-H. KRAUSE: W e  had proved possible correlations between dermatological signs 
BHAGAVAN: Do you recommend biotin supplementation in some of these patients? 
KRAUSE: A t  this t ime we cannot generally recommend such a supplementation. 
clinical symptoms due  to  low biotin status like a dermatitis or loss of hair? 
in our  patients. W e  had acne and milder form of eczema and  dermatitis. 
